First Trust Advisors LP Grows Stake in Bristol Myers Squibb Company $BMY

Key Points

• First Trust Advisors LP boosted its stake in Bristol Myers Squibb by 22.6% to 5,628,786 shares (about $253.9M), representing roughly 0.28% of the company; institutional investors now own about 76.41% of BMY.
• BMS received a key commercial boost with the FDA approval of Sotyktu for psoriatic arthritis and Reblozyl delivering >$2.3B in annualized sales, but Q4 results missed on EPS ($1.26 vs. $1.65 expected), which weighed on the stock.
• Analyst views are mixed — the consensus is a "Hold" with an average price target of $61.00 (9 Buys, 12 Holds, 1 Sell) — and the company also declared a $0.63 quarterly dividend (≈4.2% yield).

First Trust Advisors LP lifted its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 22.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 5,628,786 shares of the biopharmaceutical company's stock after purchasing an additional 1,036,238 shares during the period. First Trust Advisors LP owned about 0.28% of Bristol Myers Squibb worth $253,858,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its stake in Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after acquiring an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company's stock worth $346,000 after acquiring an additional 2,786 shares in the last quarter. United Bank boosted its holdings in Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company's stock worth $1,164,000 after acquiring an additional 3,277 shares in the last quarter. Pekin Hardy Strauss Inc. grew its stake in shares of Bristol Myers Squibb by 1.8% during the second quarter. Pekin Hardy Strauss Inc. now owns 30,962 shares of the biopharmaceutical company's stock worth $1,433,000 after acquiring an additional 540 shares during the last quarter. Finally, Chancellor Financial Group WB LP increased its holdings in shares of Bristol Myers Squibb by 32.0% during the second quarter. Chancellor Financial Group WB LP now owns 8,458 shares of the biopharmaceutical company's stock valued at $392,000 after acquiring an additional 2,050 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on BMY. Scotiabank reiterated a "sector perform" rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Bank of America upgraded shares of Bristol Myers Squibb from a "neutral" rating to a "buy" rating and upped their price target for the company from $52.00 to $61.00 in a research note on Monday, December 15th. Leerink Partners raised their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an "outperform" rating in a report on Tuesday, January 13th. Morgan Stanley reiterated an "underweight" rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Wall Street Zen raised Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Saturday, November 8th. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $61.00.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. FDA approved Sotyktu (deucravacitinib) for adults with active psoriatic arthritis — a label expansion that can broaden Sotyktu’s market opportunity and revenue runway. U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
• Positive Sentiment: BMY declared a quarterly dividend of $0.63/share (ex-dividend April 2), maintaining a high-yield payout that supports income-focused investors and can underpin the stock’s valuation. Dividend Announcement
• Positive Sentiment: Reblozyl showed positive Phase 2 results in alpha-thalassemia and has exceeded $2.3B in annualized sales — evidence Reblozyl is becoming a material growth driver as older drugs decline. Reblozyl Phase 2 Success Shapes Bristol Myers Squibb Valuation Story
• Neutral Sentiment: Bristol-Myers Squibb is tracking the real-world impact of KarXT in schizophrenia — useful clinical/market data but longer-term and unlikely to move near-term earnings. Bristol-Myers Squibb Tracks Real-World Impact of KarXT in Schizophrenia
• Negative Sentiment: Q4 results showed revenue roughly in line but EPS missed consensus (reported $1.26 vs. ~$1.65 expected), which prompted investor selling and weighed on the stock. Earnings and Market Reaction
• Negative Sentiment: Recent articles highlight a larger-than-market intraday decline and analyst focus on legacy-product pressures — shorter-term sentiment and volatility remain a risk until new product growth scales. Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $60.21 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The company has a market cap of $122.62 billion, a PE ratio of 17.45, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The company's 50 day moving average is $57.66 and its 200 day moving average is $51.01.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The business had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business's revenue was up 1.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio is presently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.